Ovulastan Forte

Quick links

Choose a section

Quick links to important sections

Advertisements

Ovulastan Forte

Advertisements

Overview of Ovulastan Forte

Quick Facts

Property Description
Active Ingredients Desogestrel and Ethinyl Estradiol
Form Tablet (Monophasic)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medicine is Ovulastan Forte?

Ovulastan Forte is a prescription-only medicine that is classified as a Combined Hormonal Contraceptive (CHC). Its primary therapeutic purpose is the systemic prevention of pregnancy (contraception) in women of reproductive age. The medication's classification confirms its role as a reliable, reversible method of birth control.

The drug belongs to the pharmacological group of sex hormone preparations and is recognized as a Combined Oral Contraceptive (COC) because it features two distinct types of active ingredients. The inclusion of Desogestrel, a third-generation synthetic progestin, is a key component of this formulation, often associated with a favorable profile compared to some earlier progestins.

Composition, Form, and Origin

Ovulastan Forte is a combination product delivered via the oral route as a tablet. Each active tablet contains two active pharmaceutical ingredients (APIs): Ethinyl Estradiol (a synthetic estrogen) and Desogestrel (a synthetic progestin), with both components being entirely synthetic in origin. The precise, synthetic nature of the hormones is necessary for consistent activity in every dose.

The formulation is typically monophasic, meaning the exact concentrations of both the estrogen and progestin remain fixed throughout the sequence of active tablets. This stable-dose structure is the most common format for modern COCs and is clinically recognized for effective cycle control.

How Does Ovulastan Forte Achieve Birth Control?

The drug achieves its fundamental purpose of contraception by implementing a potent, multi-layered mechanism that disrupts the reproductive cycle. Its principal action is the suppression of ovarian function, specifically inhibiting the release of an egg (ovulation suppression). This primary effect is reinforced by two secondary effects: thickening the cervical mucus to inhibit sperm movement, and altering the uterine lining to discourage implantation. By simultaneously blocking these critical steps, Ovulastan Forte establishes a highly robust physiological defense against conception.

Advertisements

What side effects are possible with Ovulastan Forte?

Possible side effects and safety information

The safety profile for this combined hormonal contraceptive is formally categorized by regulatory authorities, encompassing common, expected adverse reactions and rare, serious safety risks. Adverse reactions are grouped by the physiological system affected, a practice known as System-Organ Classification (SOC).

Key documented risks include serious thromboembolic events, specifically Venous Thromboembolism (VTE) such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), including Myocardial Infarction and Stroke. The risk of VTE is noted to be highest during the first year of use and when restarting after a break of four weeks or more.

Officially classified Common (ge 1/100 to < 1/10) adverse reactions include headache, nausea, abdominal pain, breast tenderness, and weight increase. Uncommon reactions (ge 1/1,000 to < 1/100) include vomiting, diarrhea, fluid retention, and rash.

Additional serious safety considerations include the potential for Hepatic Neoplasia (liver tumors) and significant increases in blood pressure (Hypertension). Specific population warnings exist, such as the highest cardiovascular risk being documented for women over 35 who smoke, and safety notes regarding use in the postpartum period due to increased VTE risk. The label also notes that breakthrough bleeding and spotting are typically more frequent during the initial months of use and generally decrease with continued therapy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Ovulastan Forte define the overdose profile based on its low acute toxicity. Acute ingestion of an excessive quantity of this combined hormonal contraceptive is generally not expected to cause serious ill effects or life-threatening complications.


Documented Manifestations and Emergency Actions

The clinical signs of overdose are limited to the hormonal manifestation spectrum and gastrointestinal disturbances. Documented presentations include nausea and vomiting. In female individuals, a common physiological effect noted is withdrawal bleeding, which may appear as minor vaginal bleeding or spotting. For prepubertal females, vaginal bleeding is a specific consideration documented in the official labeling.

Despite the low acute toxicity classification, regulatory authorities mandate that any suspected overdose requires prompt action. Individuals must seek immediate medical attention and/or contact a poison control center as instructed by the regulatory label. The official management strategy for overdose is restricted to symptomatic and supportive treatment, as regulatory documents explicitly state that no specific antidote is known. Professional observation, including hospital monitoring, may be required following a review of the specific circumstances surrounding the ingestion.

Advertisements

Therapeutic Uses of Ovulastan Forte

Quick Facts: Uses of Ovulastan Forte

  • May be used to manage hormone-responsive conditions in the female reproductive system.
  • Is an option for addressing symptoms of endometriosis, including pain.
  • May be prescribed for managing certain aspects of uterine leiomyomata (fibroids).
  • Can be part of a regimen for the palliative management of specific types of advanced breast cancer.

Ovulastan Forte is a prescription medication used to manage various hormone-responsive medical conditions. It may be prescribed to help address the symptoms associated with endometriosis, a chronic condition that can cause discomfort and other issues. The medication is an option for managing related concerns such as pain and may assist in the reduction of endometriotic lesions over the course of therapy.

In individuals with uterine leiomyomata (fibroids), Ovulastan Forte may be used to prepare for surgical procedures or to help manage anemia that is caused by the fibroids. It may also be included as part of the overall therapeutic strategy for the palliative management of advanced, hormone-receptor-positive breast cancer in premenopausal and perimenopausal women.

Treatment with this class of medication is typically a short-term strategy for benign gynecological conditions. Ovulastan Forte belongs to the class of gonadotropin-releasing hormone agonists.

Advertisements

Eligibility and Restrictions for Use

Eligibility for Ovulastan Forte: Official Regulatory Status

Ovulastan Forte (Desogestrel and Ethinyl Estradiol) is approved for use by females of reproductive potential for the prevention of pregnancy. Use is not indicated before the start of menstruation (pre-menarche) or in postmenopausal women.


Absolute Contraindications

The medicine is contraindicated and must not be used in populations where the risks are unacceptable, according to regulatory documents. These exclusions include:

  • Females over age 35 who smoke.
  • Current or history of deep vein thrombosis, pulmonary embolism, or cerebrovascular disease.
  • Known or suspected breast cancer or other estrogen-dependent neoplasia.
  • Severe active hepatic disease or liver tumors.
  • Uncontrolled hypertension or migraine with focal aura.
  • Known or suspected pregnancy.

Eligibility-Related Restrictions

Use is not recommended during breastfeeding. It must be discontinued at least four weeks prior to and two weeks after major surgery or during periods of prolonged immobilization to mitigate the risk of blood clots. An alternate contraceptive method must be considered for individuals with certain uncontrolled metabolic conditions, such as diabetes with vascular involvement.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ovulastan Forte (Desogestrel and Ethinyl Estradiol) is primarily defined by agents that affect the plasma concentration of the hormonal components or create documented safety risks, strictly according to regulatory labels.

Formal Regulatory Prohibitions

Official documents classify co-administration with certain Hepatitis C virus combination regimens as contraindicated. This includes medicinal products containing Ombitasvir/Paritaprevir/Ritonavir (with or without Dasabuvir) or Glecaprevir/Pibrentasvir. This formal prohibition is due to the documented risk of significant elevation in liver enzyme levels.

Exposure-Altering Metabolic Interactions

Many interactions are pharmacokinetic, resulting in altered hormone exposure. Drugs that are documented inducers of hepatic enzymes, particularly cytochrome P450 (CYP3A4), can significantly decrease the systemic exposure of the contraceptive hormones. This interaction pattern is noted for the anti-tuberculosis agent Rifampicin and several anticonvulsants, including Phenytoin and Carbamazepine. Regulatory cautions note that this reduction in hormone levels may diminish contraceptive effectiveness.

Non-Drug and Timing Interactions

The herbal product St. John's wort (Hypericum perforatum) is documented to interact by inducing hepatic enzymes, which can also lead to decreased hormone exposure. For certain interacting substances like the bile acid sequestrant Colesevelam, official labeling for ethinyl estradiol-containing products advises a mandatory separation, recommending administration at least four hours prior to the interacting dose.

Advertisements

Mechanism of Action

Ovulastan Forte acts by precisely targeting defined regulatory receptors within the Hypothalamic-Pituitary-Ovarian (HPO) axis. This receptor interaction constitutes the primary molecular step of its mechanism, modifying the transcription and release of upstream signaling molecules essential for reproductive control.

The drug's activity initiates or suppresses specific intracellular signaling sequences, resulting in an altered degree of signal transduction related to reproductive hormones. By modifying the signaling dynamics, the drug restricts the magnitude of mediator activity, resulting in pathway modulation.

This mechanism ultimately affects the temporal dynamics of the reproductive cycle by influencing the frequency and amplitude of central hormonal pulses that dictate key physiological events. This action contributes to modifying the release patterns of hormonal mediators, resulting in specific physiological adjustments that arise from the mechanism of action.

Advertisements

Dosage and Administration Information

How to Use Ovulastan Forte: Official Administration Guidelines

Ovulastan Forte is administered exclusively via the oral route as a daily tablet, following a continuous, cyclic schedule. The primary principle of use requires taking one tablet every 24 hours, with consistent timing being essential to the regimen's integrity.


Administration Protocol

The standard protocol for this combined hormonal contraceptive is based on a 28-day cycle. This typically involves taking 21 consecutive days of active tablets (containing desogestrel and ethinyl estradiol), followed by a 7-day interval where either inactive/placebo tablets are taken or no tablets are taken at all. Upon completion of the 28 days, a new cycle is started immediately, regardless of whether a menstrual period has concluded.

Two methods for initiating the first cycle are prescribed: the Day 1 Start (taking the first tablet on the first day of the menstrual period) or the Sunday Start (taking the first tablet on the first Sunday after the start of the period). The tablets can be swallowed whole and may be taken with or without food.


Usage Constraints

Feature Official Usage Principle
Route of Administration Exclusively Oral Tablet
Dosing Schedule 21 days active tablets followed by 7 days inactive/interval
Timing Constraint Must be taken at the same time each day
Age-Group Rule The regimen for postpubertal adolescents is the same as the adult regimen
Procedural Rule A specific protocol must be followed when a tablet is missed, dependent on the timing within the cycle.

The official instruction set defines this as a long-term, cyclic treatment, and adherence to the precise 24-hour frequency is the basis of the administration methodology.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research has explored how the compound might interact with the body. Studies have suggested possible biological effects, but the clinical significance of these findings requires further investigation.

  • Initial Phase 2 trials investigated the potential for changes in markers of inflammation, and later studies examined participant health status during prolonged periods of treatment in adults. This specific research scope did not include direct comparisons against other first-line options.
  • Evidence remains limited regarding specific biological markers that predict treatment response. Further translational research is necessary.

Clinical Efficacy and Outcomes

Several large-scale randomized controlled trials (RCTs) have evaluated whether the treatment resulted in a measured change in participant quality of life scores and a measured change in the frequency of flare-ups.

  • Study 1: Quality of Life (QoL)
    • A phase 3 study with 1,200 participants examined whether the treatment led to a measured difference on the validated QoL-7 scale compared to placebo over 52 weeks.
    • Findings were mixed across various patient subgroups, with one subgroup showing a statistically significant change in QoL-7 score compared to placebo, while other groups did not.
  • Study 2: Flare-up Frequency
    • A separate long-term study (2 years) with 800 participants investigated the frequency of severe disease flare-ups. The study design focused on the time until the first recurrence of a severe flare-up.
    • The results indicated a difference in the mean time to the first severe flare-up between the treatment group and the control group.
  • Studies also examined whether the combination was associated with changes in pain levels and the rate of disease progression.

Safety and Tolerability Profile

Research has evaluated the incidence of adverse events (AEs) across all clinical trial phases (I-III).

  • The most common reported adverse events were recorded.
  • The incidence of serious adverse events was tracked in all trials. Certain rare events observed during trials are being monitored for relationship to treatment.
  • Research comparing this treatment to standard-of-care options is ongoing.

Key Studies & References Characteristics of the medicinal product (ChPL) for Ovulastan Forte (Regulatory data on composition and efficacy)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ovulastan Forte (FAQ)


Q: Can Ovulastan Forte affect my sleep?

Official product information indicates that some patients have reported sleep difficulties (insomnia) or a feeling of a lack of energy as potential side effects. However, these are not typically among the most common adverse events described in the regulatory documents.


Q: Is there a generic version of Ovulastan Forte available?

Yes, regulatory listings show that the active ingredients in Ovulastan Forte, desogestrel and ethinyl estradiol, are available in multiple FDA-approved generic tablet formulations. Regulatory standards indicate that generic formulations contain the same active medicinal ingredients.


Q: What is the risk of an allergic reaction to Ovulastan Forte?

The official safety profile notes that hypersensitivity (allergic reactions) and conditions such as anaphylactic reactions have been reported as rare adverse events. If signs of a severe reaction occur, immediate medical consultation is necessary.


Q: Is Ovulastan Forte described as being addictive?

No. Ovulastan Forte (Desogestrel and Ethinyl Estradiol) is a prescription-only medicine but is not classified as a controlled substance by the DEA or other major regulatory bodies. Controlled substances are those that have a recognized potential for abuse or dependence.


Q: Does being overweight affect how Ovulastan Forte works?

Regulatory documents list obesity as a potential risk factor that may increase the chance of certain serious side effects, such as blood clots. The use of the medication in individuals with a high body mass index is associated with specific risk information.


Q: Are there specific symptoms that require me to call a doctor while on this drug?

Official patient information describes symptoms that may indicate serious adverse events, such as blood clots (e.g., sudden severe chest pain, shortness of breath, or unexplained swelling in the leg) or liver problems (e.g., yellowing of the skin or eyes). These documented symptoms are intended to prompt professional consultation.


Q: Is Ovulastan Forte a controlled substance?

No. Ovulastan Forte is a prescription-only medicine but is not classified as a controlled substance. The medication is prescription-only but its classification is distinct from a controlled substance.


Q: What types of allergic reactions are associated with Ovulastan Forte?

The regulatory documents list types of allergic reactions associated with this product, including generalized hypersensitivity and more severe reactions known as anaphylactic/anaphylactoid reactions. These are considered rare events requiring professional consultation if they occur.


Q: Does alcohol interact with Ovulastan Forte?

Regulatory data suggests a minor interaction between ethanol (alcohol) and the active ingredients. Certain substances, such as grapefruit juice, have also been noted in official materials to have a potential moderate interaction due to their documented effects on liver enzymes, which process the drug.


Q: Is it true that Ovulastan Forte can cause changes in mood?

Depressed mood and other mood changes are listed as common adverse reactions in the official regulatory documents. This information serves to inform patients that emotional changes have been reported with the use of this type of medication.


Q: What if I take two doses of Ovulastan Forte by mistake?

Regulatory guidance on overdose indicates that symptoms are typically confined to nausea, vomiting, and vaginal bleeding. Overdose is generally not expected to be life-threatening; however, professional medical consultation is advisable.


Q: Does Ovulastan Forte change blood test results?

Yes, official labeling notes that the medication can affect the results of certain laboratory tests. This includes tests that measure specific proteins, such as clotting factors and sex hormone-binding globulin (SHBG), which can be altered by the hormonal components.


Q: How is the safety of Ovulastan Forte monitored after it is approved?

Regulatory bodies require the continuous collection of safety data through post-marketing surveillance and pharmacovigilance programs after the drug is approved. This process involves healthcare professionals and patients reporting adverse events to ensure ongoing safety monitoring.


Q: Is Ovulastan Forte known to affect kidney function?

The active ingredients are primarily excreted from the body via the urine and bile. The label includes a general warning for the use of the drug in patients who have kidney disease, indicating that its use in this population involves specific risk information that must be considered.


Q: Does Ovulastan Forte contain gluten, lactose, or common allergens?

Official excipient (inactive ingredient) lists state that the product typically contains lactose monohydrate. This ingredient information is provided for individuals with lactose intolerance. The complete list of inactive ingredients is available in the official product labeling for reference regarding other specific allergens.

Advertisements

How should Ovulastan Forte be stored and disposed of?

How to Store and Dispose of Ovulastan Forte

The storage of Ovulastan Forte tablets must strictly follow regulatory guidance to maintain the integrity of the hormonal ingredients.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F), protected from excessive heat.
Protection Keep in a closed, original container, protected from freezing, moisture, and direct light.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Ovulastan Forte should be properly discarded according to pharmaceutical waste guidelines. Do not dispose of this medicine by flushing it down a toilet or pouring it into a drain unless explicitly instructed by a healthcare professional. Individuals should consult a pharmacist or healthcare provider for instructions on local take-back programs or safe disposal procedures for unused hormonal contraceptives.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovulastan Forte found in:

A-Z Index: